Open Access

Mild microwave ablation combined with HSP90 and TGF‑β1 inhibitors enhances the therapeutic effect on osteosarcoma

  • Authors:
    • Lingling Chen
    • Ming Wang
    • Zefeng Lin
    • Mengyu Yao
    • Wanshun Wang
    • Shi Cheng
    • Binglin Li
    • Yu Zhang
    • Qingshui Yin
  • View Affiliations

  • Published online on: May 22, 2020     https://doi.org/10.3892/mmr.2020.11173
  • Pages: 906-914
  • Copyright: © Chen et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Osteosarcoma is the most common malignant bone tumour and the second leading cause of cancer‑related death in children and adolescents. Microwave ablation has an excellent therapeutic effect on bone tumours by instantaneously increasing the temperature in the tumour; however, there is a risk of damaging the surrounding healthy tissues by exposure to a high temperature when the treatment power is too large. In the present study, two anti‑tumour reagents, a heat shock protein 90 (HSP90) inhibitor (PF‑04929113) and a transforming growth factor‑β1 (TGF‑β1) inhibitor (SB‑525334) were employed to enhance the therapeutic effect of mild‑power microwave ablation. It was revealed that microwaving to 48˚C combined with HSP90 and TGF‑β1 inhibitors significantly increased the apoptotic rate of VX2 cells. The same results were observed during in vivo experiments using New Zealand rabbits to model osteosarcoma. In addition, the results indicated that the expression of cytochrome c, caspase‑3 and caspase‑9 were upregulated in response to the treatment, which indicated that the mitochondrial apoptotic signalling pathway had been activated. These findings may provide a novel strategy for the development of microwave ablation in osteosarcoma treatment, which could effectively kill tumour cells without damaging the surrounding normal tissues.
View Figures
View References

Related Articles

Journal Cover

August-2020
Volume 22 Issue 2

Print ISSN: 1791-2997
Online ISSN:1791-3004

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Chen L, Wang M, Lin Z, Yao M, Wang W, Cheng S, Li B, Zhang Y and Yin Q: Mild microwave ablation combined with HSP90 and TGF‑β1 inhibitors enhances the therapeutic effect on osteosarcoma. Mol Med Rep 22: 906-914, 2020
APA
Chen, L., Wang, M., Lin, Z., Yao, M., Wang, W., Cheng, S. ... Yin, Q. (2020). Mild microwave ablation combined with HSP90 and TGF‑β1 inhibitors enhances the therapeutic effect on osteosarcoma. Molecular Medicine Reports, 22, 906-914. https://doi.org/10.3892/mmr.2020.11173
MLA
Chen, L., Wang, M., Lin, Z., Yao, M., Wang, W., Cheng, S., Li, B., Zhang, Y., Yin, Q."Mild microwave ablation combined with HSP90 and TGF‑β1 inhibitors enhances the therapeutic effect on osteosarcoma". Molecular Medicine Reports 22.2 (2020): 906-914.
Chicago
Chen, L., Wang, M., Lin, Z., Yao, M., Wang, W., Cheng, S., Li, B., Zhang, Y., Yin, Q."Mild microwave ablation combined with HSP90 and TGF‑β1 inhibitors enhances the therapeutic effect on osteosarcoma". Molecular Medicine Reports 22, no. 2 (2020): 906-914. https://doi.org/10.3892/mmr.2020.11173